- Home
- About AIRA
-
Ongoing Efforts
- Address Cleansing
- Adult Vaccination Capture in IIS
- FHIR and Emerging Standards
- Immunization Integration Program
- Interjurisdictional Exchange
- International Partnerships
- IIS Data Analyst Offerings
- Measurement & Improvement
- Onboarding Shared Services
- Outbreak and Response
- Technical Assistance
- Workgroups
- Events & Trainings
- Repository
-
Members Only
Moderna’s Webinar on Moderna’s mRNA Platform, Respiratory Syncytial Virus (RSV) and Updated SARS-CoV-2 (COVID-19) Vaccine for 2024-2025
Issued on August 21, 2024 by AIRA
Open Resource:
• Introduction to mRNA Technology and Vaccine Development: This segment will explore the fundamental principles of the mRNA platform and its application in vaccine development, highlighting the advantages and potential uses of mRNA-based vaccines.
• Current Burden of Disease Analysis: We will review the latest data concerning the impact of COVID-19 and RSV in the US, focusing on the ongoing challenges these viruses pose.
• 2024-2025 mRNA Vaccines for COVID-19 and RSV: Discuss the upcoming fall season's mRNA vaccine options, detailing their formulations, mechanisms of action, and safety profiles to ensure a well-rounded understanding for the 2024-2025 vaccination efforts.
• Current Burden of Disease Analysis: We will review the latest data concerning the impact of COVID-19 and RSV in the US, focusing on the ongoing challenges these viruses pose.
• 2024-2025 mRNA Vaccines for COVID-19 and RSV: Discuss the upcoming fall season's mRNA vaccine options, detailing their formulations, mechanisms of action, and safety profiles to ensure a well-rounded understanding for the 2024-2025 vaccination efforts.